Brokerages Set Perspective Therapeutics, Inc. (NYSE:CATX) Price Target at $15.14

Shares of Perspective Therapeutics, Inc. (NYSE:CATX) have been assigned an average recommendation of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $15.14.

A number of research firms have weighed in on CATX. UBS Group initiated coverage on shares of Perspective Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $20.00 price objective for the company. Bank of America lowered shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the stock from $24.00 to $5.00 in a report on Monday, November 25th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. Royal Bank of Canada dropped their target price on shares of Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating for the company in a report on Monday, November 25th. Finally, Truist Financial began coverage on Perspective Therapeutics in a research note on Wednesday, September 25th. They issued a “buy” rating and a $21.00 target price for the company.

Perspective Therapeutics Stock Down 5.5 %

Shares of CATX opened at $4.11 on Friday. Perspective Therapeutics has a one year low of $2.28 and a one year high of $19.05. The stock has a 50-day moving average of $10.44 and a two-hundred day moving average of $12.21.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21). The business had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. On average, equities analysts expect that Perspective Therapeutics will post -0.88 earnings per share for the current year.

Insider Transactions at Perspective Therapeutics

In other Perspective Therapeutics news, CEO Johan M. Spoor purchased 14,500 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was purchased at an average cost of $3.78 per share, with a total value of $54,810.00. Following the completion of the acquisition, the chief executive officer now directly owns 152,072 shares of the company’s stock, valued at $574,832.16. This trade represents a 10.54 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Jonathan Robert Hunt acquired 12,829 shares of the business’s stock in a transaction on Monday, November 25th. The shares were bought at an average cost of $3.82 per share, for a total transaction of $49,006.78. Following the acquisition, the chief financial officer now owns 48,800 shares of the company’s stock, valued at $186,416. This represents a 35.66 % increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 33,595 shares of company stock worth $126,625 over the last ninety days. Company insiders own 3.52% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of CATX. nVerses Capital LLC acquired a new stake in Perspective Therapeutics during the 3rd quarter worth $57,000. US Bancorp DE increased its position in shares of Perspective Therapeutics by 142.7% during the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after purchasing an additional 3,866 shares in the last quarter. Victory Capital Management Inc. purchased a new stake in shares of Perspective Therapeutics in the 2nd quarter valued at about $117,000. Point72 DIFC Ltd acquired a new stake in shares of Perspective Therapeutics in the 2nd quarter valued at about $118,000. Finally, Intech Investment Management LLC purchased a new position in Perspective Therapeutics during the 3rd quarter worth approximately $137,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.